Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Ovid Therapeutics Inc.NASDAQ: OVID
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures outflow grows to $0
Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was $0.
Context
- Capital expenditures amounted to 0.0% of revenue in FY2025, down 12.5 pp from a year earlier.
- Capital expenditures increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (71K) | +48.3% |
| FY2023 | 2023-12-31 | (137.46K) | +90.3% |
| FY2022 | 2022-12-31 | (1.42M) | -649.1% |
| FY2021 | 2021-12-31 | (189.41K) | — |
Capital Expenditures vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 capital expenditures of $0 is the smallest of the 11 companies compared; the peer median is $926.5K.
- Its year-over-year change of +100.0% is the 6th highest of 11, against a peer median of +81.5%.
- Capital expenditures amounts to 0.0% of revenue for OVID, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.62M | +113.0% | -56.0% | 13.3% | |
| LTM Mar 2026 | $9.32M | +140.4% | -65.5% | 1.4% | |
| LTM Mar 2026 | $7.51M | +140.5% | +294.4% | 51.6% | |
| LTM Jun 2026 | $3.38M | +718.6% | -69.0% | 61.6% | |
| LTM Mar 2026 | $1.95M | -4.2% | +1.4% | 5.3% | |
| LTM Mar 2026 | $981.99K | +43.1% | -19.2% | 1.4% | |
| LTM Mar 2026 | $871K | +153.9% | -44.7% | 2.7% | |
| LTM Mar 2026 | $669.4K | -56.0% | -19.0% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $432K | +50.0% | -23.9% | — |
| LTM Mar 2026 | $169K | -96.0% | -62.9% | — | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding OVID) | $926.5K | +81.5% | -34.3% | 5.3% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 119.84M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Depreciation & Amortization | 237K | 1.38M | 1.6M | 613K | 273K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Change in Working Capital | (16.81M) | (8.23M) | 2.39M | (150K) | (4.1M) |
| Accounts Receivables | 141.76K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.7M | (5.17M) | 1.75M | (512K) | (1.23M) |
| Other Working Capital | (18.66M) | (3.06M) | 635.51K | 362K | (2.87M) |
| Other Non-Cash Items | 15.35M | (764.94K) | (4.71M) | (36.26M) | (21.9M) |
| Operating Cash Flow | 118.61M | (55.23M) | (45.78M) | (55.96M) | (38.33M) |
| Capital Expenditures | (189.41K) | (1.42M) | (137.46K) | (71K) | 0 |
| Acquisitions (Net) | (1.63M) | (2.5M) | (10M) | 0 | 0 |
| Purchases of Investments | (1.63M) | (172.96M) | (112.44M) | (73.25M) | (91.85M) |
| Sales of Investments | 0 | 90M | 120M | 128M | 42M |
| Other Investing Activities | (5.4K) | (1M) | (97.15K) | (89K) | 0 |
| Investing Cash Flow | (1.82M) | (87.88M) | (2.58M) | 54.59M | (49.85M) |
| Debt Repayment | 0 | 0 | 30M | 0 | 0 |
| Common Stock Issued | 925.4K | 180.66K | 535.2K | 622K | 75.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.31K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Effect of Forex Changes | (1.93M) | 0 | 0 | 0 | (167K) |
| Net Change in Cash | 115.76M | (142.93M) | (17.83M) | (740K) | (13.15M) |
| Free Cash Flow | 118.42M | (56.65M) | (45.92M) | (56.03M) | (38.33M) |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.